TAP Block , Intrathecal Morphine Or Their Combination For Post Operative Analgesia Following TAH

Efficacy Of Transversus Abdominis Plane Block , Intrathecal Morphine Or Their Combination For Post Operative Analgesia Following Total Abdominal Hysterectomy.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06882369

Enrollment

Registered

2025-03-18

Start date

2024-11-01

Completion date

2025-07-31

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative Pain Management

Brief summary

This randomized controlled clinical trial designed to evaluate the efficacy of transversus abdominis plane (TAP) block, intrathecal morphine, or their combination in postoperative pain relief, as assessed by time to first analgesic request, pain scores, total postoperative analgesic consumption, time of ambulation, complications and hemodynamics following total abdominal hysterectomy.

Interventions

PROCEDURETAP Block

The transabdominal plane (TAP) block is a regional anesthesia technique used for postoperative pain management in abdominal wall procedures, providing somatic analgesia to the anterior and lateral abdominal walls

DRUGIntrathecal morphine injection

Intrathecal injection of morphine plus 20 mg hyperbaric bupivacaine in spinal anesthesia

DRUGspinal anesthesia

intrathecal injection of bupivacaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Female patients aged 30 to 70 years. * Elective total abdominal hysterectomy. * ASA physical status I or II. * Willingness to provide informed consent.

Exclusion criteria

* Refusal of the block. * Allergy to study medications. * Preexisting coagulation disorders. * Local infection at the site of needle insertion. * Uncontrolled respiratory or cardiac disorders. * Impaired kidney or liver function.

Design outcomes

Primary

Measure	Time frame	Description
Time to first analgesic request	24 hours	Time (in hours) until the patient demand additional analgesia.

Secondary

Measure	Time frame	Description
Total analgesic consumption	24 hours	Cumulative postoperative analgesic consumption
Time to ambulation	24 hours	Time (in hours) from arrival in the PACU until the patient was able to walk.
complications	24 hours	Incidence of nausea, vomiting, pruritus, respiratory depression, hematoma, infection or hemodynamic instability

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026